正丹股份(300641.SZ):加快推進 1.5 萬噸/年高分子特種樹脂單體系列產品項目建設進度,爭取及早投產
格隆匯5月6日丨正丹股份(300641.SZ)接受特定對象調研時,有投資者問及"公司後續發展規劃?"
答:(1)公司後續將繼續聚焦主業,加快偏苯三酸酐、T0TM和均四甲苯產能的釋放,持續擴大經營規模,利用公司核心技術在偏苯三酸酐、T0TM 等優勢細分市場進一步做強做大。
(2)進一步優化公司的產品結構,延伸碳九芳烴綜合利用產業鏈,加快推進氧化反應尾氣綜合利用制氮項目(年產 4.8 萬噸液氮和 4,000萬 Nm3 高純氮氣)以及技術改造等項目的建設,擴大產品品種及產能,增加企業效益。
(3)加快推進 1.5 萬噸/年高分子特種樹脂單體系列產品項目建設進度,爭取及早投產,1 萬噸/年均四甲苯裝置技改項目、偏苯三酸酐裝置餘熱回收節能技改項目,增長公司盈利水平,提高公司核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.